Atgam ( Lymphocyte immunoglobulin antithymocyte) injection from Pfizer is used for ;
1. Prevention and treatment of acute renal allograft rejection
2. Prevention of graft-vs-host disease (GVHD) in bone marrow transplant (BMT) patients.
3. Treatment of aplastic anemia in patients not suitable for BMT.
Dose and Administration:
A test dose (0.1 mL of a freshly prepared 0.05 mg/mL solution in NS) may be given intradermally. The patient and injection site is examined every 15 min for one hr. However, a negative test does not guarantee a reaction-free administration. Also, a positive reaction does not always mean that the drug cannont be used with extreme caution if it is absolutely essential (risk/benefit analysis is necessary).
Before each dose, the patient may be pretreated with diphenhydramine (Benadryl) and acetaminophen (Tylenol).
The ATGAM dose must be diluted in normal saline or 1/2 normal saline to a concentration not exceeding 4 mg/mL. If the drug is to be given via a peripheral line (not recommended) the concentration should be less than 1 mg/mL.
The ATGAM dose should be administered via iv infusion into a central line over a minimum of 4 â 8 hrs. Infusion should be stopped immediately if a systemic reaction (dyspnea, tachycardia, hypotension, or a generalized skin reaction) or anaphylaxis occurs.
Acute Renal Allograft Rejection: 15 mg / kg q24h for 14 days, then give q48h for 7 more doses for a total of 21 doses in 28 days. Therapy should be discontinued if severe thrombocytopenia or leukopenia occurs.
Aplastic Anemia: 15 mg / kg q24h for 10 days, then give q48h for 7 more doses. Another protocol which is used only in adults calls simply for 40 mg/kg q24h for 4 days.
No pharmacokinetic drug interactions have been described.
Excessive immunosuppression can occur when used in combination with other immunosuppressive agents.
904, 9th floor, Sunshine Tower, Senapati Bapat Marg, Dadar West, Mumbai, Maharashtra, 400012, India